Company profile: Bluejay Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical drug candidates for infectious diseases, including BJT-778, a fully human IgG1 monoclonal antibody designed to neutralize and facilitate clearance of HDV virions, contributing to a potential functional cure for CHB/CHD, and BJT-628, an oral liver-targeted HBV transcript inhibitor reducing HBsAg. Offers the Bluejay L-TAP platform for liver-targeted oral delivery and runs Phase 1/2a trials in chronic hepatitis B.
Products and services
- BJT-628: An orally bioavailable, liver-targeted HBV transcript inhibitor that reduces hepatitis B surface antigen production and enhances efficacy in combination therapies for chronic hepatitis B
- BJT-778: A fully human IgG1 monoclonal antibody that neutralizes and facilitates clearance of HDV virions, contributing to a potential functional cure for CHB and CHD
- Bluejay L-TAP: A proprietary liver-targeting platform that enhances delivery of oral small molecules to the liver, improving treatment efficacy and safety for liver diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bluejay Therapeutics
Hyglos
HQ: Germany
Website
- Description: Provider of bacteriophage-derived recombinant proteins for detection and removal of harmful bacteria, leveraging bacteriophage biochemical principles to develop target-specific protein tools for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hyglos company profile →
Abac Therapeutics
HQ: Spain
Website
- Description: Provider of precision antimicrobial drug discovery and development, creating first-in-class, pathogen-specific antibiotics for MDR Gram-negative infections. Offers the PasNas scalable, multiplexed platform to identify high-quality leads across compounds and bacterial species, and advances agents with suitable pharmacokinetics/toxicology, leveraging public-private collaborations to combat antimicrobial resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abac Therapeutics company profile →
ContraFect
HQ: United States
Website
- Description: Provider of biotechnology research focused on monoclonal antibodies to treat life-threatening infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ContraFect company profile →
Trius Therapeutics
HQ: United States
Website
- Description: Provider of discovery, development and commercialization of innovative antibiotics for life-threatening infections. Completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI, with IV and orally administered formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trius Therapeutics company profile →
Great Basin Scientific
HQ: United States
Website
- Description: Provider of molecular, rapid diagnostic testing solutions, featuring the Great Basin Diagnostic System, a fully automated sample-to-result platform with integrated reagents and internal controls. Offers assays including Staph ID/R Blood Culture Panel, Stool Bacterial Pathogens, C. diff, Group B Strep, and Shiga Toxin Direct tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Great Basin Scientific company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bluejay Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bluejay Therapeutics
2.2 - Growth funds investing in similar companies to Bluejay Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bluejay Therapeutics
4.2 - Public trading comparable groups for Bluejay Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →